Will Intas’ Cut-Price Avastin Biosimilar Disrupt The Market?

Intas Pharmaceuticals has introduced its biosimilar bevacizumab in India at less than half the innovator product’s price, putting the spotlight on how its competition might tackle the new entrant’s pricing position.